Connect with us

Cannabis News

Idaho Medical Marijuana Campaign Says Legalization Ballot Measure Would Generate $100 Million In Annual Sales

Published

on

Idaho could see more than $100 million in medical marijuana sales and up to $28 million in new revenue for state coffers under a legalization measure activists are working to put on the November ballot, according to a new economic analysis released by the campaign.

The Natural Medicine Alliance of Idaho (NMAI) announced this last week collected enough signatures for an initiative to legalize medical cannabis To pass the statewide threshold for ballot qualification, it commissioned the firm Younger Associates to do two fiscal projections of the proposal, using Utah’s medical marijuana program as a model.

“Based on Utah’s participation trajectory, Idaho supports approximately 63,000 active patients and $108.5 million in annual retail sales by Year 6,” the analysis states.

Under the first revenue scenario, a 6 percent state sales tax would be applied to marijuana sales and there would also be a $100 annual patient registration fee, which would generate about $6.5 million in sales tax revenue and $6.3 million by the program’s sixth year.

The second revenue scenario includes the same patient registration cost and sales tax, but also adds an additional 14 percent fee collected at the point of sale. It would generate about $21.7 million a year in tax and fee revenue, in addition to about $6.3 million in annual patient card fees, to bring in $28 million a year from the state.

“Actual revenue will ultimately depend on the final program design and implementation decisions made by the State.” the report he says

In addition to the economic analysis, the NMAI also released a new short video this month saying the measure proposes “strictly regulated market access” for cannabis and treats patients “with dignity rather than fear or stigma.”

The video also features medical marijuana as an “alternative to the devastating effects of opioids” and the initiative “supports local jobs, Idaho agriculture and generates tax revenue while maintaining strong enforcement standards to prevent misuse.”

“This is not about recreation, it’s about care,” he said he says. “The law provides medical freedom to patients to consult with their physician about their health conditions and assert their right to make choices about their own care.”

But since it’s unclear how many signatures the campaign has collected so far and whether activists have met another requirement for petitions to be distributed regionally, NMAI continues to hold signature-gathering events across the state to expand its coalition of supporters ahead of the May 1 submission deadline.

Amanda Watson, communications manager for NMAI, told Marijuana Moment on Wednesday that organizers “feel very confident that we will qualify for the ballot in November.”

As of this week, NMAI has collected more than 73,000 total signatures — surpassing the statewide requirement of 70,725 for valid petitions — according to the campaign’s website.

To be certified on the ballot, the group must also submit the signatures of at least 6 percent of registered voters in at least 18 of the state’s 35 legislatures. Marihuana Moment reached out to NMAI for a status update on progress toward that goal, but a representative was not immediately available.

Meanwhile, groups of paid and volunteer applicants they are expanding across the state to high-traffic areas to collect signatures, and the NMAI website has a map showing where registered voters can go to sign.

The Idaho Medical Cannabis Act, introduced by NMAI last October, would provide patients with access to marijuana from a limited number of dispensaries and provide a regulatory framework for the market.

Here are the main provisions Idaho Medical Cannabis Law:

  • Healthcare practitioners may recommend medical cannabis to patients with conditions including cancer, anxiety and acute pain.
  • Medical marijuana patients or designated caregivers can purchase up to 113 grams of cannabis for smoking or 20 grams of THC extract for vaporization per month.
  • The state would issue three vertically-integrated cannabis business licenses, and then potentially six licenses in total.
  • Marijuana would be reclassified under state law, Title II.
  • State and local law enforcement would be prohibited from assisting in drug enforcement activities related to the state’s illegal cannabis program.
  • There would be anti-discrimination protections for those who use or sell marijuana in compliance with state laws, preventing adverse actions by employers, landlords and educational institutions.
  • There does not seem to be any equity-based reform, nor will the initiative be given the opportunity to grow at home.

“We believe Idahoans deserve access to legal, compassionate and natural care right at home,” NMAI’s website states. “Our mission is to provide patients with a legal path to natural medicine to relieve suffering and restore dignity without the fear of addiction.”

“The Idaho Medical Cannabis Act is our first step. It creates a safe and strictly regulated medical program that allows qualified Idahoans to seek medical treatment for cannabis with a valid diagnosis from a health care provider.” he says. “It supports Idaho agriculture, generates tax revenue to reinvest locally and ensures patients can find natural relief.”

Last month, the campaign also released the results of a statewide poll shows that 83 percent of likely voters support the legalization of medical cannabisincluding 74% of Republicans, 95% of Democrats and 92% of independents.

When asked how they would vote if the current legalization of cannabis appears on the November ballot, 76% of respondents said “yes”. Of that cohort, 50 percent said they would “definitely” vote yes, while only 21 percent said they would vote “no.”

After introducing the medical cannabis initiative last year, a separate 2024 campaign, Kind Idaho, told supporters it would cancel its signature drive. ballot initiative to legalize the personal possession and cultivation of marijuana the adults

Pleasant Idaho previously put medical marijuana ballot measures before voters Both in the 2022 and 2024 elections, but the efforts were unsuccessful.

Meanwhile, this year voters will see a different type of proposal on the ballot: the constitutional amendment approved by the legislature to make it so. only members of the legislature can legalize marijuana or other controlled substances.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

Lawmakers held a separate hearing last March to discuss it bill to legalize medical cannabisbut in the following months there has been no significant action on the matter.

Separately, it would be a bill from last year by Rep. Bruce Skaug (R). set a mandatory minimum fine of $420 for possession of cannabisremoving judges’ discretion to apply lower sentences. Skaug said the bill, which ultimately stalled in committee, would send a message that Idaho is tough on marijuana.

Members of the House of Representatives were also admitted bill to ban marijuana adsalthough the Senate later defeated the measure.

user photo Max Pixel.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

Concert Series Specials launched for state medical cannabis patients

Published

on

By











Post Dispensary, Kentucky’s first medical cannabis dispensary, is connecting with patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Madisonville, Hopkinsville and surrounding areas by aligning unique specials with the region’s summer concert calendar. Located at 300 N Main St. in Beaver Dam, minutes from major highways connecting these vibrant cities.

This summer, The Post Dispensary is offering special pricing and incentives for Concert Series Events at the Beaver Dam Amphitheater, SPARKS in the Park 4th of July celebration and surrounding events, such as Owensboro’s ROMP Festival (June 24-27, 2026). Patients can stop by before or after shows for big savings.

“We’re more than just a booty,” said a dispensary representative. “From Owensboro’s world-class ROMP Festival to Beaver Dam’s Amphitheater events, we’re making it convenient and budget-friendly for patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Hartford and beyond to combine our love of music with compassionate care and an affordable product.”

The Post Dispensary hosts regular Patient Guidance events on the second Saturday of every month. These units have professionals on hand to assess patients and issue written certificates at low cost, application support and expert consultations in a welcoming environment. The next Patient Drive aligns perfectly with summer travel patterns, making it easy for patients from Owensboro, Bowling Green, Elizabethtown, Madisonville, Henderson, Madisonville and surrounding towns to plan a trip to Beaver Dam that combines care with community and entertainment.

For more information:
Post-Dispensary
thepostdispensary.com/










Continue Reading

Cannabis News

Missouri GOP Lawmakers Hope Trump’s Psychedelics Order Boosts Efforts To Allow Military Veteran Access In The State

Published

on

By

“Congratulations to President Trump for stepping up and taking the lead on this. PTSD is a killer among veterans.”

By Rebecca Rivas, Missouri Independent

Missouri state representative Dave Griffith has spent the past five years researching how psychedelic-assisted therapy has helped veterans struggling with post-traumatic stress disorder and depression.

His last legislative session in the House ended this May, and he pushed legislation for the last time allow clinical trials of psychedelic-assisted therapy in Missouri. In the final days of the session, the bill stalled in the Missouri Senate after passing the House with overwhelming support.

“I’m not going to be there next year, I’m term-limited,” said Griffith, a Republican who served as chairman of the House Veterans Affairs and Armed Services Committee. “It’s really about passing the torch to a lot of other veterans who are on the Veterans Commission and see the value in that.”

He was hopeful when he saw an announcement The US Department of Veterans Affairs announced last week a new clinical trial to evaluate the safety and effectiveness of methylenedioxymethamphetamine-assisted therapy.or MDMA-assisted therapy. MDMA is a synthetic substance made in a laboratory, according to the department, and is also called “ecstasy” or “molly” in recreational use.

“Congratulations to President Trump for stepping up and taking the lead on this,” said Griffith of Jefferson City. “PTSD is a killer among veterans. If you just listen to the testimony that’s been happening over the last five years in the Missouri House, the life-changing it’s been for them is a compelling reason why something like this works.”

A new trial follows Trump signed an executive order in April, “Expediting Medical Treatment for Serious Mental Illness.” The order aims to increase participation in clinical trials and accelerate innovative research models and drug approvals for psychedelics.

Directs the Secretary of Health and Human Services to allocate at least $50 million to support and collaborate with state governments that “have established or are developing programs to advance psychedelic drugs for serious mental illness.”

Without passing the legislation, Missouri will miss this opportunity, said Republican state representative Matthew Overcast of Ava.

Cloud hoped that Trump’s April order would help “grease the wheels” this year by state Rep. Richard West and state Rep. Richard West who sponsored the state to conduct a study on psilocybin and ibogaine therapy.

“The last couple of months there’s been a lot of feds on things that the states are reluctant to move forward with here,” Overcast said. “So it’s exciting.”

According to the VA’s announcement, the department is involved in 19 other active clinical trials focused on psychedelic therapies for mental health conditions that have received more than $23 million in outside funding.

The new trial, called “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in US Veterans,” will enroll about 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and those receiving the same psychotherapy with an active placebo. VA is coordinating with the US Food and Drug Administration and plans to share trial data with FDA.

The trial will be conducted at the VA Providence Healthcare System, and will recruit veterans from the Providence, Rhode Island, campus in West Haven, Connecticut, and the VA Connecticut Healthcare System.

Trump’s executive order says there have been more than 6,000 veteran suicides per year for more than 20 years, and the current veteran suicide rate is twice that of the adult non-veteran population.

He says people with major depressive disorder and substance abuse disorder, among other serious mental illnesses, may relapse or fail to respond fully to standard medical and psychiatric therapies.

“Despite significant federal investment in research into potential advances in mental health care and treatment, our medical research system has yet to produce approved therapies that promote lasting improvements in the mental health status of the most complex patients,” the order states. “Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription drugs.”

Missouri veterans John and Kara Grady, who own a hemp shop in Rosebud, strongly agree with the statement, they said. And they’d like to see Missouri’s veterans health system participate in clinical trials already underway.

“President Trump is opening up investigations for the veteran community,” said John Grady, “If you look at the numbers … we’ve lost more in the wars with mental health than we’ve lost.”

The lack of movement on psychedelic-assisted therapy legislation is among the reasons why John Grady is running for state representative over Bruce Sassmann in the state’s Republican primary.

“If you don’t agree with Trump on everything, at least he’s addressing this veteran issue right here,” Grady said. “Hopefully, we’ll be able to stop that number, we’ll stop that flow of our precious veterans dying by their own hands because they don’t have treatment.”

This story was first published by the Missouri Independent.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Germany’s medical cannabis imports post first quarterly decline since early 2024

Published

on

By

German imports of medical cannabis flowers fell to 50.5 tonnes in the first quarter of 2026, down from 60.8 tonnes in the previous quarter, the decline from the first quarter of 2024. According to a new EU and UK market update from Whitney Economics.

The drop lands against a year that went backwards. Germany took in more than 2025 tonnes of the product in 2025, more than double the 72,850 kilograms recorded in 2024, and import volumes have risen every year since 2018, when the figure remained below 4,500 kilograms. The first quarter number continues to match the high pace of 2025, which is why the report treats it as an early sign of stabilization rather than a turnaround.

Prices
The volume has not created a stable price. A gram of cannabis in a German pharmacy is approaching 4 euros, while a gram on the illegal market is around 8 euros, reversing the usual relationship between regulated and unregulated supply. The wholesale price is around 2 euros per gram, roughly half the retail price at the pharmacy. Pharmacy prices breached 3.99 euros in November 2025, and the report puts the overall compression close to 25% in two and a half years.

Germany legalized ownership in 2024 and restricted sales to pharmaceutical and telemedicine providers. Two access roads run parallel. Medical cannabis is mainly prescribed through private prescriptions, and recreational cannabis is available through membership of a cannabis association, with 400 licensed cultivation associations across the country, although the exact count varies by source. It is the medical segment that drives market growth, not the recreational segment.

Growth is based on telemedicine
Patients fill out an online questionnaire, receive a prescription from an affiliated physician, and in many cases have their order filled through an integrated pharmacy partner, with delivery within days and, in some cities, within hours. Between 600,000 and 700,000 self-employed consumers are supported by the telemedicine industry, compared to 200,000 to 300,000 medical patients supported by pharmacies. Total imports are now sufficient to supply between 900,000 and one million consumers.

© Philiprowe | Dreamstime

Market exposure
Critics argue that commercial interests risk overshadowing the medical nature of the system, and treatment does not always meet the required standard of control. Legislative initiatives that would tighten the framework are already on the table, including mandatory in-person inquiries and a ban on distribution of mail requests. The likely result of both measures is a significant decline in demand for medical cannabis flowers. Many telemedicine companies are preparing for the opportunity by building networks with local doctors and pharmacies.

Where patients and consumers would go if medical access is curtailed is an open question, as the recreational market lacks a real alternative for patients and cannabis clubs continue to face licensing hurdles at the state level.

Part of the difficulty in reading the market is that import figures say less than they seem. More cannabis is entering the country than ever before, but how much is reaching consumers and what the actual demand is is unclear. Without a nationwide data framework, the market functions as a black box, and excess supply and actual demand are difficult to measure with great precision. Supply has tended to expand faster than the market can absorb, with no forecast to confirm mature demand, and prices have adjusted downward as a result.

Germany has had a signal effect across Europe since the start of its reform, although its model has drawn criticism, with the mixing of medical and recreational consumption a recurring complaint. Countries that have traditionally taken a conservative line, France among them, have gone to a more formalized medical field, under stricter conditions and without adopting the medical flower like Germany.

For more information:
Whitney Economics
Beau Whitney
(503) 724-3084
www.whitneyeconomics.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media